H1 2026 Private Bio/Pharma Funding: Environment Remained Challenging
- 1 hour ago
- 4 min read
H1 2026 private bio/pharma funding reached its highest total amount invested of the past three years, but the number of funding events declined by almost 33%. Total capital increased slightly compared with H1 2024 and H1 2025, while funding activity remained well below prior-year levels. This points to an investment environment where capital is still available, but fewer companies are securing it.
In total, private companies raised approximately $20.3B across 366 funding events in H1 2026, compared with ~$19.7B across 535 events in H1 2025 and ~$19.2B across 684 events in H1 2024. The 366 funding events in H1 2026 represent a 32% decline over the 535 events of H1 2025.Â
With respect to quarterly changes, Q2 showed some improvement in the amount of capital invested over Q1. Private funding reached approximately $9.24B, up from ~$7.7B in Q2 2025. However, deal volume declined from 234 to 153 events, showing that funding was concentrated across a smaller group of companies.
Private Funding Activity
Private funding activity remained muted in H1 2026, with 366 total events, down 32% from 535 in H1 2025 and down 46% from 684 in H1 2024 (Table 1 & Fig. 1).
Q2 2026 recorded 153 events, compared with 234 in Q2 2025 and 381 in Q2 2024.
April recorded 46 events, followed by 40 in May and 67 in June.
Q2 deal volume declined by approximately 35% year over year and 60% compared with Q2 2024.
Grant activity totaled 66 events in H1 2026, including 22 during Q2.
June was the strongest month of Q2 by event count, with 67 funding announcements, including 17 grants. This represents an improvement from April and May, although activity remained below comparable periods in 2024 and 2025.
Overall, the data suggests that private funding activity began to improve toward the end of Q2, but the market remains significantly more selective than in prior years
Table 1. H1 Private Bio/Pharma Funding Snapshot (2024–2026)
H1 2024 | H1 2025 | H1 2026 | |
Total Funding | ~$19.2B | ~$19.7B | ~$20.3B |
Total Events | 684 | 535 | 366 |
Grants | 85 | 79 | 66 |
Early-Stage Funding | ~$5.94B | ~$5.40B | ~$3.97B |
Early-Stage Events | 229 | 198 | 137 |
Note: Funding amounts reflect disclosed values. Event counts include disclosed and undisclosed financings.
Total Private Funding Amounts
Despite lower deal volume, the total amount invested was slightly elevated during H1 2026 (Fig. 2).
H1 2026 private funding totaled approximately $20.3B, compared with ~$19.7B in H1 2025 and ~$19.2B in H1 2024.
Q2 2026 funding reached approximately $9.24B, up from ~$7.7B in Q2 2025 but below the ~$11.0B recorded in Q2 2024.
April totaled approximately $1.99B, followed by $3.74B in May and $3.51B in June.
Q2 2026 therefore recorded approximately 20% more funding than Q2 2025, despite having around 35% fewer events. Compared with Q2 2024, funding declined by approximately 16%, while the number of events fell by around 60%.
Early-Stage Funding
Early-stage funding remained under pressure in H1 2026, although activity improved during Q2, particularly in June (Fig. 3).
H1 2026 early-stage funding totaled approximately $3.97B across 137 events, down from ~$5.40B across 198 events in H1 2025 and ~$5.94B across 229 events in H1 2024.
Q2 2026 recorded approximately $1.70B across 64 Pre-Seed, Seed, and Series A events.
June was the strongest month of Q2 for both early-stage funding and event volume. This represents a meaningful improvement from the weaker activity observed earlier in the quarter. Series A rounds accounted for approximately $1.51B of the $1.70B raised during Q2, while Seed rounds contributed approximately $189.1M and Pre-Seed rounds only $2.1M.
Despite the Q2 improvement, early-stage funding remained approximately 16% below Q2 2025 and 45% below Q2 2024. Early-stage event volume also declined from 110 events in Q2 2024 and 81 in Q2 2025 to 64 in Q2 2026.
The data suggests that early-stage investment began to recover toward the end of the quarter, but the broader funding environment remains difficult for newly formed and very early-stage companies.
Public Market Sentiment
Public bio/pharma markets strengthened significantly during Q2 2026.
The largest AUM balanced public biotech ETF, XBI, increased 23.9% during Q2Â and approximately 30.2% across H1, reflecting improved sentiment toward small- and mid-cap public biotechnology companies. The largest AUM large-cap biotech-weighted ETF, IBB, gained 12.6% during Q2Â and approximately 12.5% across H1.
Public bio/pharma companies also raised approximately $21.0B across 140 funding events during Q2, including equity, debt, grants, and other financing types.
Overall, stronger public-market performance coincided with improved private funding in June. It will be interesting to see if this translates into a sustained recovery in private biotech deal volume.
Concluding Remarks
H1 2026 private biotech funding reached approximately $20.3B, slightly above H1 2024 and H1 2025. However, event volume fell sharply, and early-stage activity remained below prior-year levels.
Stronger public markets and improved private funding activity in June provide a more positive ending to H2 2026. Still, the recovery remains selective, with capital concentrated across fewer companies. We previously predicted, and continue to believe, that continued strength in the biotech public markets will drive an increase in private biotech funding during the 2nd half of 2026.
Data Source: BiopharmIQ
About DHL
Double Helix Law helps innovative life sciences companies and investors build, evaluate, and protect strategically valuable IP positions. We often operate less like traditional outside counsel and more like an embedded fractional IP department, working closely with clients to build stronger patent portfolios, navigate difficult IP and freedom-to-operate situations, and support financings, acquisitions, and strategic diligence. Our lower-overhead operating model allows deeper strategic integration for better results. Learn more about DHL and meet the team.
Want to stay updated on life science patent law? Subscribe to get notified of updates
The content on this website (including all pages, articles, and comments) is not legal advice, and does not and is not intended to form or constitute any attorney-client relationship. The content is not a solicitation for business; it is for educational and entertainment purposes only, and reflects the personal views of the author(s) only and not those of any past, present, or future client of DHL. Any content should be double-checked for accuracy and current applicability, and liability is disclaimed for any error or omission.
7/15/26 Published (MD, RF, EJV)